Urodynamix Technologies commences uroNIRS 2000 pilot program

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Oct 8 2009Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announces that it has commenced a pilot sales and marketing program with Cardinal Health for its uroNIRS 2000, an innovative technology for the non-invasive diagnosis of bladder conditions. The 90-day pilot program will be used to by Urodynamix and Cardinal Health to evaluate the viability of adding the uroNIRS 2000 to Cardinal Health's catalogue of offerings to the urology market.

The uroNIRS 2000 provides a real-time, non-invasive evaluation of the bladder function during voiding to aid in the diagnosis of bladder outlet obstruction. The product is approved for sale in the U.S.

Source:

Urodynamix Technologies Ltd.

Posted in: Device / Technology News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes
Bladder and gut fermentation syndromes: Uncommon disorders with significant implications
New analysis sheds light on cancer incidence and mortality trends in the UK
How do different organ microbiomes influence neuropsychiatric disorders?
Understanding giggle incontinence: Causes, symptoms, and management
Nanobots for bladder cancer treatment, promising high efficacy and targeted delivery
Study reveals nerve changes linked to pain and urinary frequency in recurrent UTI sufferers
Unlocking the secret drivers of deadly pancreatic cancer: New target offers hope for treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study shows linear associations between body mass index and site-specific tumors in young males